{"nctId":"NCT02354235","briefTitle":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","startDateStruct":{"date":"2015-01"},"conditions":["Type 2 Diabetes Mellitus"],"count":138,"armGroups":[{"label":"Canagliflozin + Teneligliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Teneligliptin","Drug: Canagliflozin"]},{"label":"Placebo + Teneligliptin","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Teneligliptin","Drug: Placebo"]}],"interventions":[{"name":"Teneligliptin","otherNames":["Tenelia, MP-513"]},{"name":"Canagliflozin","otherNames":["Canaglu, TA-7284"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women who are 20 - 75 years old\n* HbA1c of ≥7.0% and \\<10.5%\n* FPG of ≤ 270 mg/dL\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period\n\nExclusion Criteria:\n\n* Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes\n* Patients with serious diabetic complications\n* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification\n* Patients with severe hepatic disorder or severe renal disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)","description":"The change from baseline in percentage of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.10"},{"groupId":"OG001","value":"-0.10","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose Level","description":"The change from baseline in fasting plasma glucose level collected at Week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.9","spread":"3.4"},{"groupId":"OG001","value":"3.9","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Body Weight From Baseline","description":"The percentage change from baseline in body weight collected at Week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.32","spread":"0.31"},{"groupId":"OG001","value":"-0.99","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the AUC(0-2h) for Postprandial Plasma Glucose (PPG)","description":"The change from Baseline in AUC(0-2h) for Postprandial Plasma Glucose collected at Week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-105.9","spread":"7.6"},{"groupId":"OG001","value":"-5.6","spread":"8.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Postprandial Plasma Glucose Level","description":"The change from baseline in 2-hour postprandial plasma glucose level collected at Week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.1","spread":"4.9"},{"groupId":"OG001","value":"-9.2","spread":"5.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":70},"commonTop":["Nasopharyngitis"]}}}